Brief: Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress
12/05/2026 22:55
May 12 (Reuters) - BridgeBio Oncology Therapeutics Inc BBOT.O: BBOT REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS BRIDGEBIO ONCOLOGY THERAPEUTICS INC: CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO 2028 Source text: ID:nGNX59LM2n Further company coverage: BBOT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bridgebio Oncology Therapeutics
See all newsBrief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Bridgebio Oncology Therapeutics - May Offer Up To $500 Million In Securities - SEC Filing
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
BridgeBio Oncology Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress